NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis $0.84 -0.01 (-1.66%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rani Therapeutics Stock (NASDAQ:RANI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rani Therapeutics alerts:Sign Up Key Stats Today's Range$0.84▼$0.8650-Day Range$0.63▼$0.9252-Week Range$0.44▼$3.87Volume371,367 shsAverage Volume716,756 shsMarket Capitalization$117.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones. Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery. In addition to its insulin candidate, the company is exploring oral formulations of GLP-1 receptor agonists and other therapeutic proteins. Rani has secured investigational new drug (IND) approvals and completed initial safety and pharmacokinetic assessments in humans, positioning its RaniPill platform for broader application across multiple chronic disease areas. Headquartered in San Jose, California, Rani Therapeutics leverages collaborations with research institutions and industry partners to streamline development and manufacturing. While still in the clinical stages, the company is preparing for pivotal trials and regulatory interactions to support future commercialization. Rani’s management team combines expertise from pharmaceutical development, medical device engineering and regulatory affairs, underscoring its commitment to transforming biologic drug delivery and expanding patient access globally.AI Generated. May Contain Errors. Read More Rani Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreRANI MarketRank™: Rani Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 254th out of 919 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingRani Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRani Therapeutics has a consensus price target of $8.75, representing about 941.7% upside from its current price of $0.84.Amount of Analyst CoverageRani Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Rani Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rani Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rani Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.99% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 14.14, which indicates bearish sentiment.Change versus previous monthShort interest in Rani Therapeutics has recently decreased by 3.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.85 News SentimentRani Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Rani Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for RANI on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows2 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Rani Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $50,040.00 in company stock, which represents 0.0427% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,040.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.73% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions30.19% of the stock of Rani Therapeutics is held by institutions.Read more about Rani Therapeutics' insider trading history. Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RANI Stock News HeadlinesQ4 EPS Estimate for Rani Therapeutics Decreased by AnalystAugust 27 at 1:29 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)August 25, 2026 | theglobeandmail.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)HC Wainwright Reiterates Buy Rating for Rani Therapeutics (NASDAQ:RANI)August 23, 2026 | americanbankingnews.comCanaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)August 20, 2026 | theglobeandmail.comRani Therapeutics (NASDAQ:RANI) Coverage Initiated at Chardan CapitalAugust 20, 2026 | americanbankingnews.comRani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate UpdateAugust 13, 2026 | globenewswire.comRani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth ConferenceAugust 10, 2026 | markets.businessinsider.comSee More Headlines RANI Stock Analysis - Frequently Asked Questions How have RANI shares performed this year? Rani Therapeutics' stock was trading at $1.35 at the start of the year. Since then, RANI stock has decreased by 37.8% and is now trading at $0.84. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The business had revenue of $1.71 million for the quarter, compared to the consensus estimate of $0.93 million. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an initial public offering on Thursday, July 29th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are Rani Therapeutics' major shareholders? Top institutional investors of Rani Therapeutics include AWM Investment Company Inc. (6.05%), BlackRock Inc. (1.34%), Spruce Street Capital LP (1.34%) and Almitas Capital LLC (1.19%). Insiders that own company stock include South Cone Investments Limited, Mir A Imran, Talat Imran, Kate Mckinley, Alireza Javadi and Cortes Isidoro Alfonso Quiroga. View institutional ownership trends. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rani Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO). Company Calendar Last Earnings8/13/2026Today8/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 RANI's financial health is in the Red zone, according to TradeSmith. RANI has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RANI CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees110Year Founded2012Price Target and Rating Average Price Target for Rani Therapeutics$8.75 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+941.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.67 million Net MarginsN/A Pretax Margin-685.34% Return on Equity-104.60% Return on Assets-65.17% Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.31 Sales & Book Value Annual Sales$1.63 million Price / Sales71.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book2.47Miscellaneous Outstanding Shares139,400,000Free Float102,135,000Market Cap$117.10 million OptionableOptionable Beta0.78 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:RANI) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLeading AI Insider Issues Urgent Market WarningA leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
